Implantable therapeutic device
A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
1. An ophthalmic drug delivery system comprising:
an extended release device configured to be implanted in an eye, the device comprising:
a reservoir having a reservoir volume; and
a rigid porous structure coupled to the reservoir having a plurality of interconnecting, irregularly shaped channels, the porous structure located at a distal region of the reservoir, the rigid porous structure having a release rate tuned to release a predetermined rate profile of a drug formulation from the reservoir and into the eye to treat the eye for an extended period of time; and
a drug formulation contained in and delivered by the extended release device, wherein the drug formulation comprises an inhibitor of complement factor D having a concentration in a solution volume and a given half-life upon bolus injection of the solution volume into the eye,
wherein the extended release device is tuned to the drug formulation by selecting a value for at least one of the group consisting of: the concentration, the reservoir volume, and the release rate, to achieve an effective half-life in the eye when the drug formulation is delivered by the implantable extended release device,
wherein the effective half-life is longer than the given half-life; and
wherein the rigid porous structure has a porosity P between about 3% to about 70% corresponding to the percentage of void spaces extending within the rigid porous structure.
2. The system of claim 1 , wherein the given half-life is within a range from about 1 hour to about 9 days.
3. The system of claim 1 , wherein the effective half-life is within a range from about 18 days to about 250 days.
4. The system of claim 1 , wherein the reservoir volume is within a range from about 10 uL to about 50 uL.
5. The system of claim 1 , wherein the reservoir is refillable.
6. The system of claim 1 , wherein the reservoir is flushable.
7. The system of claim 1 , wherein the target body volume is the vitreous of the eye.
8. The system of claim 1 , wherein the effective half-life in the target body volume maintains a concentration of the drug in the target body volume that is above a therapeutic target concentration for a longer period of time than the given half-life maintains the concentration of the drug in the target body volume that is above the therapeutic target concentration.
9. The system of claim 1 , wherein the rigid porous structure is coupled to a distal end of the reservoir near an outlet of the reservoir.
10. The system of claim 1 , wherein the inhibitor of complement factor D blocks Complement Factor D-mediated cleavage of Complement Factor B.
11. The system of claim 1 , wherein the inhibitor of complement factor D treats age-related macular degeneration or geographic atrophy.